Display options
Cite
Di Guardo F, Ciotta L, Monteleone M, et al. Male Equivalent Polycystic Ovarian Syndrome: Hormonal, Metabolic, and Clinical Aspects. Int J Fertil Steril. 2020;14(2):79-83doi: 10.22074/ijfs.2020.6092.
Di Guardo, F., Ciotta, L., Monteleone, M., & Palumbo, M. (2020). Male Equivalent Polycystic Ovarian Syndrome: Hormonal, Metabolic, and Clinical Aspects. International journal of fertility & sterility, 14(2), 79-83. https://doi.org/10.22074/ijfs.2020.6092
Di Guardo, Federica, et al. "Male Equivalent Polycystic Ovarian Syndrome: Hormonal, Metabolic, and Clinical Aspects." International journal of fertility & sterility vol. 14,2 (2020): 79-83. doi: https://doi.org/10.22074/ijfs.2020.6092
Di Guardo F, Ciotta L, Monteleone M, Palumbo M. Male Equivalent Polycystic Ovarian Syndrome: Hormonal, Metabolic, and Clinical Aspects. Int J Fertil Steril. 2020 Jul;14(2):79-83. doi: 10.22074/ijfs.2020.6092. Epub 2020 Jul 15. PMID: 32681618; PMCID: PMC7382675.
Copy Download .nbib Format: NLM
Share it on

Int J Fertil Steril. 2020 Jul;14(2):79-83. doi: 10.22074/ijfs.2020.6092. Epub 2020 Jul 15.

Male Equivalent Polycystic Ovarian Syndrome: Hormonal, Metabolic, and Clinical Aspects.

International journal of fertility & sterility

Federica Di Guardo, Lilliana Ciotta, Morena Monteleone, Marco Palumbo

Affiliations

  1. Department of General Surgery and Medical Surgical Specialties, University of Catania, Catania, Italy.Electronic Address: [email protected].
  2. Department of General Surgery and Medical Surgical Specialties, University of Catania, Catania, Italy.

PMID: 32681618 PMCID: PMC7382675 DOI: 10.22074/ijfs.2020.6092

Abstract

Recent studies identified the presence of a male polycystic ovarian syndrome (PCOS), which mainly affects men whose female relatives are afflicted with PCOS, caused by genes responsible for the susceptibility of this syndrome in women. Similar hormonal, metabolic, and clinical alterations occurring in PCOS women have also been reported in their male relatives, suggesting a association between the male and female forms of the syndrome. Although the remarkable clinical manifestation of the male equivalent PCOS is diagnosed by the early-onset androgenetic alopecia, character-ized by hair recession, pronounced hypertrichosis, insulin resistance, biochemical and hormonal abnormalities, the hormonal/metabolic profile is still controversial. Men affected by early-onset androgenetic alopecia (AGA) are at risk of developing hyperinsulinemia, insulin-resistance, dyslipidaemia, and cardiovascular diseases. However, there is no consensus on the association of male equivalent PCOS with hypertension and obesity. Moreover, reduced levels of sex hormone-binding globulin have been detected in these male patients, accompanied by increased free androgens. Conversely, literature reported lower concentrations of testosterone in male equivalent PCOS when compared with the normal range, indicating a crucial role for the conversion of cortical androgens. Finally, further studies are warranted to investigate a possible link among AGA, metabolic/hormonal alterations, and acne. Our study assessed the hormo-nal, metabolic and clinical aspects of male equivalent PCOS syndrome reported in the literature to evaluate similar and divergent elements involved in the female version of the syndrome.

Copyright© by Royan Institute. All rights reserved.

Keywords: Androgenetic Alopecia; Insulin Resistance; Polycystic Ovarian Syndrome

Conflict of interest statement

The authors declare no conflicts of interest.

References

  1. Endocr Regul. 2005 Dec;39(4):127-31 - PubMed
  2. JAMA Dermatol. 2016 Apr;152(4):399-404 - PubMed
  3. Ann N Y Acad Sci. 1951 Mar;53(3):708-28 - PubMed
  4. Br J Dermatol. 2010 Apr;162(4):786-9 - PubMed
  5. Exp Clin Endocrinol Diabetes. 2004 Jan;112(1):24-8 - PubMed
  6. J Am Acad Dermatol. 2011 Jul;65(1):48-53 - PubMed
  7. Med Hypotheses. 2007;68(3):480-3 - PubMed
  8. Lancet. 2000 Sep 30;356(9236):1165-6 - PubMed
  9. Br J Dermatol. 2012 Aug;167(2):306-13 - PubMed
  10. Int J Trichology. 2015 Oct-Dec;7(4):141-7 - PubMed
  11. J Complement Integr Med. 2019 Sep 17;17(2): - PubMed
  12. Int J Trichology. 2013 Apr;5(2):69-72 - PubMed
  13. Clin Endocrinol (Oxf). 1993 Jun;38(6):653-8 - PubMed
  14. Actas Dermosifiliogr. 2010 Apr;101(3):248-56 - PubMed
  15. J Biol Chem. 2013 May 31;288(22):15937-46 - PubMed
  16. Sb Lek. 2000;101(1):17-22 - PubMed
  17. Fertil Steril. 1996 Dec;66(6):942-7 - PubMed
  18. Reprod Biomed Online. 2005 Jun;10(6):713-20 - PubMed
  19. Br J Dermatol. 2010 Aug;163(2):371-7 - PubMed
  20. Physiol Res. 2004;53(3):287-94 - PubMed
  21. Reprod Biol. 2016 Mar;16(1):53-60 - PubMed
  22. Eur J Dermatol. 2011 Jan-Feb;21(1):79-82 - PubMed
  23. Med Hypotheses. 2019 May;126:1-3 - PubMed
  24. Dermatol Res Pract. 2015;2015:980310 - PubMed
  25. Cent Eur J Public Health. 2006 Jun;14(2):78-81 - PubMed
  26. J Clin Endocrinol Metab. 2007 Apr;92(4):1289-95 - PubMed
  27. J Endocrinol Invest. 2018 Jan;41(1):49-57 - PubMed
  28. Clin Endocrinol (Oxf). 2004 Mar;60(3):322-8 - PubMed
  29. J Pediatr Endocrinol Metab. 2000;13 Suppl 5:1307-9 - PubMed
  30. Endocrine. 2012 Dec;42(3):555-60 - PubMed
  31. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2014 Sep;43(5):597-601 - PubMed
  32. JAMA Dermatol. 2016 Sep 1;152(9):986-91 - PubMed
  33. Curr Pharm Des. 2019;25(22):2467-2473 - PubMed
  34. Gynecol Obstet Invest. 1989;28(1):23-30 - PubMed
  35. South Med J. 1975 Nov;68(11):1359-65 - PubMed

Publication Types